| [1] |
Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2):95-111.
|
| [2] |
Matsuo K, Rocha FG, Ito K, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients[J]. J Am Coll Surg, 2012, 215(3):343-355.
|
| [3] |
Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma[J]. Hepatology, 2011, 53(4):1363-1371.
|
| [4] |
Ruys AT, Busch OR, Rauws EA, et al. Prognostic impact of preoperative imaging parameters on resectability of hilar cholangiocarcinoma[J]. HPB Surg, 2013:657309.
|
| [5] |
Tilleman EH, de Castro SM, Busch OR, et al. Diagnostic laparoscopy and laparoscopic ultrasound for staging of patients with malignant proximal bile duct obstruction[J]. J Gastrointest Surg, 2002, 6(3):426-430.
|
| [6] |
中华医学会外科学分会胆道外科学组，解放军全军肝胆外科专业委员会．肝门部胆管癌诊断和治疗指南（2013版）[J]．中华外科杂志，2013,51(10):865-871.
|
| [7] |
Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016, 27 suppl 5:v28-37.
|
| [8] |
中国抗癌协会．肝门部胆管癌规范化诊治专家共识（2015）[J]．中华肝胆外科杂志，2015,21(8):505-511.
|
| [9] |
Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence[J]. Ann Surg, 2008, 248(2):273-279.
|
| [10] |
Cheng QB, Yi B, Wang JH, et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV[J]. Eur J Surg Oncol, 2012, 38(12):1197-1203.
|
| [11] |
Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection[J]. Ann Surg, 2005, 241(1):77-84.
|
| [12] |
Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection[J]. Ann Surg, 2001, 233(3):385-392.
|
| [13] |
Giuliante F, Ardito F, Guglielmi A, et al. Association of lymph node status with survival in patients after liver resection for hilar cholangiocarcinoma in an Italian multicenter analysis[J]. JAMA Surg, 2016, 151(10):916-922.
|
| [14] |
Matsuyama R, Mori R, Ota Y, et al. Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction[J]. Ann Surg Oncol, 2016, 23 Suppl 4:475-484.
|
| [15] |
Pichlmayr R, Weimann A, Tusch G, et al. Indications and role of liver transplantation for malignant tumors[J]. Oncologist, 1997, 2(3):164-170.
|
| [16] |
Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma[J]. Ann Surg, 2005, 242(3):451-458.
|
| [17] |
Gores GJ, Gish RG, Sudan D, et al. Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia[J]. Liver Transpl, 2006, 12(12 Suppl 3):S95-97.
|
| [18] |
Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers[J]. Gastroenterology, 2012, 143(1):88-98, e3.
|
| [19] |
Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease[J]. Ann Surg, 2018, 267(5):797-805.
|
| [20] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
|
| [21] |
Rogers JE, Law L, Nguyen VD, et al. Second-line systemic treatment for advanced cholangiocarcinoma[J]. J Gastrointest Oncol, 2014, 5(6):408-413.
|
| [22] |
Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase Ⅱstudy of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805)[J]. Cancer Sci, 2013, 104(9):1211-1216.
|
| [23] |
Takahara N, Isayama H, Nakai Y, et al. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study[J]. Invest New Drugs, 2017, 35(3):269-276.
|
| [24] |
Mizusawa J, Morizane C, Okusaka T, et al. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)[J]. Jpn J Clin Oncol, 2016, 46(4):385-388.
|
| [25] |
Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30(16):1934-1940.
|
| [26] |
Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study[J]. Lancet Oncol, 2010, 11(12):1142-1148.
|
| [27] |
Jensen LH, Lindebjerg J, Ploen J, et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer[J]. Ann Oncol, 2012, 23(9):2341-2346.
|
| [28] |
Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer[J]. J Clin Oncol, 2006, 24(19):3069-3074.
|
| [29] |
Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study)[J]. Cancer, 2016, 122(4):574-581.
|
| [30] |
Iyer RV, Pokuri VK, Groman A, et al. A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer[J]. Am J Clin Oncol, 2016, DOI: 10.1097/COC.0000000000000347. |
| [31] |
Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site-when a biomarker defines the indication[J]. N Engl J Med, 2017, 377(15):1409-1412.
|
| [32] |
Czink E, Kloor M, Goeppert B, et al. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer[J]. Cold Spring Harb Mol Case Stud, 2017, 3(5):a001974.
|